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A new clonal strain of Candida auris is an emerging 
etiologic agent of fungemia in Delhi, India. In 12 patients 
in 2 hospitals, it was resistant to fluconazole and genotypi-
cally distinct from isolates from South Korea and Japan, 
as revealed by M13 and amplified fragment length poly-
morphism typing.
In 2009, yeast isolates from the external ear canal of a Japanese patient were identified as a new species, Can-
dida auris, on the basis of sequence analysis of the nuclear 
rRNA gene. The species is phylogenetically related to C. 
haemulonii (1). In the same year, 15 isolates of C. auris 
were reported from otitis media patients in South Korea (2). 
Genotyping of these isolates revealed a clonal origin (3). In 
addition, in 3 patients, persistent fungemia caused by C. 
auris was resistant to fluconazole; 2 of these patients died 
(4). Fungemia caused by C. auris seems to be extremely 
rare, however. We report a series of fungemia cases caused 
by a new clonal strain of this emerging pathogen, involving 
12 inpatients from 2 hospitals in Delhi, India.
The Study
We characterized 12 bloodstream C. auris isolates, 
originating from an equal number of patients, collected 
during 2009–2011 at 2 hospitals (a tertiary care general 
hospital and a pediatric center) in Delhi, India. The con-
trols included reference strains of C. auris from South 
Korea (CBS12372, CBS12373) and Japan (JCM15448, 
DSMZ21092), C. haemulonii (CBS7801–7802, CBS5149, 
CBS5150), C. pseudohaemulonii (KCTC1787, CBS10004, 
JCM12453), and C. duobushaemulonii (CBS7798–7800, 
CBS9754).
The yeast isolates were oval without pseudohyphae 
and germ tube formation. They appeared pink on CHROM- 
agar Candida medium (Difco, Becton Dickinson, Balti-
more, MD, USA) and grew at 37°C and 42°C. VITEK2 
(bioMérieux, Marcy I’Etoile, France) misidentified 10 
isolates as C. haemulonii and 2 as C. famata. Similarly, 
API20C (bioMérieux) also misidentified them as C. sake. 
C. auris isolates from India assimilated N-acetylglucos-
amine (NAG) in contrast to the isolates from Japan and 
South Korea.
Molecular identification was done by sequencing in-
ternal transcribed spacer (ITS) and D1/D2 regions (5–7). 
ITS sequences (GenBank accession nos. KC692039–
KC692050) of our isolates showed 100% homology with 
an unrelated C. auris isolate (GenBank accession no. 
HE797773) and 98% identity with isolates from Japan 
and South Korea (GenBank accession nos. AB375772 
and EU884189). Also, large ribosomal subunit sequences 
(GenBank accession nos. KC692053–KC692064) of the 
India isolates showed 100% homology with an unrelated 
C. auris isolate (GenBank accession no. HE797774) and 
98%–100% identity with isolates from Japan and South 
Korea (accession nos. AB375773 and EU881960). ITS 
and large ribosomal subunit sequences of the isolates 
in our study showed 85%–98% similarity with the clos-
est C. haemulonii complex species. These isolates have 
been deposited at the CBS-KNAW Fungal Biodiversity 
Centre, Utrecht, the Netherlands (accession nos. 
CBS12766–CB12777).
M13 PCR fingerprinting analysis was performed as 
described (8,9). The isolates from India had a distinct band-
ing pattern in relation to isolates from Japan and South Ko-
rea. Except for 2 isolates (CBS12772, CBS12776), the C. 
auris isolates showed an identical banding pattern, suggest-
ing a single genotype (Figure 1). The isolates’ genotypic 
diversity was also determined by using amplified fragment 
length polymorphism (AFLP) fingerprint analysis (10). 
In a dendrogram in which standard Pearson and UPGMA 
(unweighted pair group method with averages) settings 
were used, C. auris isolates clustered separately from C. 
haemulonii, C. duobushaemulonii, and C. pseudohaemulo-
nii. The C. auris isolates from India showed a clonal origin 
and were genotypically distinct from the isolates from Ja-
pan and South Korea (Figure 2).
Antifungal susceptibility testing was done by using 
microbroth dilution according to Clinical Laboratory Stan-
dards Institute protocols (11). All isolates showed high 
geometric mean MICs of fluconazole (Pfizer, Groton, CT, 
USA) (28.5 mg/L), whereas isavuconazole (Basilea Phar-
maceutica, Basel, Switzerland [now Astellas]), posacon-
azole (Schering-Plough, Kenilworth, NJ, USA [now 
Merck]), itraconazole (Lee Pharma, Hyderabad, India), 
and voriconazole (Pfizer) exhibited highly potent activity. 
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Amphotericin B (Sigma-Aldrich, St. Louis, MO, USA), 
flucytosine (Sigma-Aldrich), and the 3 echinocandins also 
showed excellent activity (Table).
Clinical features of the infections and response to 
antifungal therapy of the 12 patients with fungemia are 
summarized in the online Technical Appendix Table 
(wwwnc.cdc.gov/EID/article/19/10/13-0393-Techapp1.
pdf). Each patient had at least 3 predisposing risk factors. 
Seven had immunosuppressive conditions: 6 (50%) had 
diabetes mellitus, 5 (42%) had chronic kidney disease, 2 
(17%) had undergone cancer chemotherapy, and 1 (8%) 
was infected with HIV. Of the 5 children, 3 were infants 
of low birthweight, 1 neonate had late onset sepsis, and 
one 10-year-old child had acute lymphoblastic leukemia. 
Having an indwelling urinary catheter was the predomi-
nant risk factor for 83% of patients, followed by receiv-
ing broad-spectrum antimicrobial drugs (75%), spending 
time in an intensive care unit (58%), having neutrope-
nia (50%), and having a central venous catheter (CVC) 
(42%). Notably, 7 (58%) patients had breakthrough 
fungemia while receiving fluconazole (1–3 weeks), and 
persistent candidemia developed in 9 (75%) patients. In 
8 of these 9 patients, candidemia cleared after antifungal 
therapy in 1–3 weeks. For the remaining 3 patients, blood 
culture reports were available post mortem. C. auris 
represented 5% of the annual candidemia cases in a pe-
diatric hospital and 30% of annual candidemia cases in a 
tertiary care general hospital. Overall mortality rates as 
high as 50% were noted; 30% of deaths were attributed 
to critical illness.
Conclusions
This study documents the emergence of a new clon-
al strain of C. auris as an etiologic agent of candidemia 
in India. Fungemia caused by C. auris is extremely rare, 
identified only by sequencing. Because diagnostic labo-
ratories do not undertake molecular identification rou-
tinely, fungemia is likely to be much more prevalent 
than published reports indicate. Growth at 40°C may 
differentiate C. auris isolates, routinely misidentified as 
C. haemulonii by VITEK. C. haemulonii does not grow 
at 40°C, as does C. auris (12). Sequencing may confirm 
their identity.
Although Lee et al. proposed negative assimilation of 
NAG for differentiating C. auris from C. pseudohaemulo-
nii, this proposal seems invalid because all isolates from 
India assimilated NAG (4). The phenotypic divergence of 
these isolates was also supported by M13 and AFLP typing. 
Notably, C. auris isolates from 2 hospitals in Delhi were 
clonal, suggesting interhospital transmission. Transmis-
sion of the same genotype was observed in intensive care, 
surgical, medical, oncologic, neonatal, and pediatric wards, 
which were mutually exclusive with respect to health care 
personnel. This finding is analogous to that of the clonal 
transmission of C. auris among 3 hospitals in South Korea 
(2). Prevalence of a unique clonal strain of C. auris in 2 
hospitals in Delhi, 13.5 km apart, underscores the need for 
more comprehensive studies to determine potential occur-
rence of other endemic clones in various regions of India.
Because most (83%) of the patients in our study had an 
indwelling urinary catheter, the source of fungemia could 
be urogenital colonization. However, no urine samples 
were cultured. Five (42%) patients had a CVC in situ, but 
Figure 1. M13 PCR fingerprinting of Candida auris isolates. Lane 
1, 50-bp ladder (New England BioLabs, Evry, France); lane 2, C. 
duobushaemulonii reference isolate (CBS7798); lanes 3–6, C. 
auris isolates from South Korea (KCTC 17809 and KCTC 17810), 
Japan (DSMZ21092 and JCM 15448), and reference isolates; and 
lane 7–18, 12 test isolates from India.
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none received total parenteral nutrition. Although Candida 
spp. adhere to intravascular catheters, providing a potential 
nidus for infection, a previous study showed that C. auris 
does not form a biofilm (3). Catheter tip cultures were neg-
ative for 3 of the 5 patients who had a CVC. Although 57% 
of patients admitted to critical care units died, the role of C. 
auris candidemia in fatal cases could not be ascertained be-
cause no comparison was available with a population that 
did not have candidemia.
C. auris assumes a greater clinical significance for 
the successful management of candidemia because all the 
reported isolates, including the new isolates, were flucon-
azole resistant (2,4). Most patients in this study had persis-
tent candidemia, and mortality rates were as high as 33%.
In conclusion, C. auris is an emerging yeast pathogen 
that is underreported because it is misidentified in routine 
diagnostic laboratories. The resistance of C. auris to fluco-
nazole is particularly worrisome.
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Figure 2. Dendrogram of amplified 
fragment length polymorphism analysis of 
Candida auris isolates from India, Japan, 
and South Korea and members of C. 
haemulonii complex. It was constructed 
by using UPGMA (unweighted pair group 
method with averages) in combination 
with the Pearson correlation coefficient 
and was restricted to fragments of 60–400 
bp. Scale bar indicates the percentage 
similarity.
 
Table. Results of In vitro antifungal susceptibility testing of 12 Candida auris isolates originating from fungemia patients in 2 hospitals, 
Delhi, India, 2009–2011 
MIC, mg/L*  
Drug† 
AMB FLU ITC VRC ISA POS FC CAS MFG AFG 
MIC50 0.25 32 0.125 0.5 0.125 0.125 0.125 0.25 0.06 0.25 
MIC90 0.5 64 0.25 1 0.25 0.25 0.125 0.25 0.125 0.5 
GM 0.33 28.5 0.15 0.39 0.10 0.12 0.125 0.23 0.072 0.26 
Range 0.25–1 16–64 0.125–0.25 0.125–1 <0.015–0.25 0.06–0.25 0.125 0.125–0.25 0.06–0.125 0.125–0.5 
*MIC50, 50% minimum inhibitory concentration; MIC90, 90% minimum inhibitory concentration; GM, geometric mean of MICs. 
†AMB, amphotericin B; FLU, fluconazole; ITC, itraconazole; VRC, voriconazole; ISA, isavuconazole; POS, posaconazole; FC, flucytosine; CAS, 
caspofungin; MFG, micafungin; AFG, anidulafungin. 
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